Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
Status:
Completed
Trial end date:
2017-06-15
Target enrollment:
Participant gender:
Summary
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in
Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.